Genomic & Biopharma NewsUK’s MRC Tech licenses antibody to Chinese group
UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading China-based drug development process solutions provider, for development of a novel therapeutic for treatment of Hepatitis C virus infection.
|PharmaTimes, 2017-03-15 10:06:26|
Gene Expression’s Big Rethink
Genetic Engineering News by Richard Stein – Two technologies used to interrogate gene expression, RNA-Seq and microarray analysis, often return strongly correlated results. These technologies, however, have not been evaluated for their concordance at the isoform level. To understand the correlation between RNA-Seq and exon-array platforms in detecting isoforms, Dr. Davuluri and colleagues compared gene- ...
|Transcriptome Research & Industry News, 2017-03-15 10:00:52|
Targeting lncRNA to reduce heart failure in pulmonary hypertension
An article published in Experimental Biology and Medicine identifies a new signaling pathway that promotes heart failure in pulmonary hypertension. The study, led by Dr. Matthias Brock, from the Division of Pulmonology, University Hospital of Zurich, University of Zurich in Switzerland, reports that inhibition of MALAT1, a long noncoding RNA, reduces heart hypertrophy in mice ...
|lncRNA Research and Industry News, 2017-03-15 10:00:45|
Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Cancer Testing
Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces a collaboration with Catalyst Pharmaceuticals for the provision of Biocept’s Target Selector™ platform to screen patients diagnosed with LEMS for early onset or recurrence of small cell lung cancer ...
|Exosome RNA Research & Industry News, 2017-03-15 10:00:14|
The Science of Science Advocacy
Should researchers advocate for the inclusion of science in public policymaking?
|The Scientist, 2017-03-15 10:00:00|
Allergan signs up to Editas’ genome editing tech
Allergan has secured itself exclusive access to Editas Medicine’s genome-editing ocular programmes under a strategic research and development pact between the two firms.
|PharmaTimes, 2017-03-15 09:56:25|
US approves Merck’s Keytruda for Hodgkin lymphoma
Merck’s immunotherapy Keytruda has been approved by US regulators to treat both adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
|PharmaTimes, 2017-03-15 09:50:23|
Study: Investigational Ebola vaccine regimen induced immune response that persisted for one year
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
|News Medical Life Sciences, 2017-03-15 09:43:37|
PJK risk following lumbar spinal fusion depends on level of spine fused, study shows
The surgical correction of adult spinal deformities often involves realigning the lower portion of the spine, or the 'lumbar' spine.
|News Medical Life Sciences, 2017-03-15 09:25:37|